In this paper antinociceptive and anti-edematous effects are examined of the essential oils of the underground parts of two Balkan endemic Laserpitium species (Apiaceae), L. zernyi and L. ochridanum. Furthermore, the essential oil of the underground parts of L. ochridanum is chemically characterised by GC and GC-MS. Antinociceptive and anti-edematous effects were measured in a rat model of localized inflammation, induced by carrageenan, using apparatus for the modified paw-pressure test, and plethysmometer, respectively. The effects of both Laserpitium essential oils were measured after oral gavage administration to male Wistar rats in doses of 25, 50 and 100 mg/kg. The main constituents of L. ochridanum essential oil were: α-pinene (33.2%), α-bisabolol (10.3%) and chamazulene (14.9%). The essential oil of L. zernyi was previously shown to be rich in α-pinene (31.6%) and α-bisabolol (30.9%). Both examined essential oils produced a significant dose-dependent antinociceptive effect. The corresponding ED 50 ±SEM in producing antinociception were 45.9±4.9 mg/kg and 42.4±2.1 mg/kg for L. zernyi and L. ochridanum oil, respectively. Both essential oils also significantly reduced paw edema in a dose-dependent manner. The estimated ED 50 ±SEM values for the anti-edematous effect were 36.3±4.5 mg/kg for L. zernyi oil and 45.1±11.3 mg/kg for L. ochridanum oil. These results suggest that the essential oils of both investigated Laserpitium species may be effective against pain and edema present in various inflammatory conditions. Keywords: Laserpitium zernyi, Laserpitium ochridanum, Essential oil, Antinociceptive activity, Anti-edematous activity.
Inflammation is a normal protective response to tissue injury caused by physical trauma, noxious chemicals, microbiological agents, and even autoimmune disease. It is the most common cause of clinical pain. Unfortunately, the drugs currently available to treat pain and inflammation are associated with several side effects. The current trend of research is the investigation of natural products because of their high effectiveness with minimal side effects [1, 2] . Essential oils have been widely used in the pharmaceutical and cosmetic industry [3] , and their biological properties are generally determined by their major components. Since the essential oils are usually very complex mixtures, it is generally assumed that a synergy of ingredients will contribute to the exerted therapeutic effect [4, 5] .
Laserpitium L. (Apiaceae) species are aromatic perennial plants, some of them being used in European folk medicine [6] . L. zernyi Hayek [7] is an endemic of the mountain regions of the central Balkans, and was previously treated as a subspecies of L. siler subsp. zernyi (Hayek) Tutin [8] . L. ochridanum Micevski is an endemic of Mt. Galičica in the Former Yugoslav Republic of Macedonia (FYROM) [9] . From the underground parts of these two Laserpitium species, sesquiterpene lactones were isolated, mainly of the guaianolide class, amongst which highly esterified ones expressed significant cytotoxic activity. Five guaianolides of the slovanolide type obtained from L. ochridanum were novel compounds [10] . In the hydrodistilled, pale blue essential oil from the underground parts of L. zernyi, the major compounds detected were α-pinene (31.6%) and α-bisabolol (30.9%). The oil showed significant activity against some Gram (+) bacteria (Staphylococcus epidermidis, S. aureus and Micrococcus luteus) [6] . In this study, the antinociceptive and anti-edematous activities of the essential oils hydrodistilled from the underground parts of these Laserpitium species, together with the composition of L. ochridanum essential oil were investigated for the first time.
The air-dried underground parts of L. ochridanum yielded 1.99%, w/w, of a dark blue essential oil with a pleasant, aromatic odor. The results of GC and GC-MS analysis of this essential oil are given in Table 1 . Forty-four compounds were identified (94.3% of the total oil), the main ones being α-pinene (33.2%), chamazulene (14.9%), α-bisabolol (10.3%) and bicyclogermacrene (8.7%). Other components were found in quantities less than 3.2% or in traces (<0.05%). For the investigation of antinociceptive and antiedematous activities, a rat model of localized inflammation induced by carrageenan was used, and the essential oils were applied in a dose range of 25 -100 mg/kg (p.o.).
Antinociceptive activity was measured in a modified paw pressure test. Significant, dose-dependent antinociception was observed with both oils (Fig. 1A and B) . The maximal effects of the L. zernyi essential oil were 38.6, 53.9 and 61.7% for doses of 25, 50 and 100 mg/kg, respectively (small graph in Fig. 1A) , and estimated ED 50 ± SEM (95% confidence limits) was 45.9 ± 4.9 (11.7- According to available data, only α-pinene and ()-α-bisabolol, the main constituents of both examined Laserpitium essential oils, have been examined in regard to their effects on nociception. In a mouse writhing test, a model of acute nociception, which also has an inflammatory component, α-pinene (500 mg/kg, p.o.) produced an insignificant antinociceptive effect [11] . On the other hand, Rocha et al. [12] have shown that ()-α-bisabolol (25 -200 mg/kg, p.o.) significantly diminished mechanical inflammatory hypernociception of the paw evoked by carrageenan and reduced nociceptive behavior in a writhing test, as well as in a second, inflammatory phase of the paw formalin test in mice. In vitro studies showed that ()-α-bisabolol inhibits cyclooxygenase (COX), an enzyme involved in the production of prostaglandins (PGs) [13a,b] . Among other proinflammatory substances, PGs play an important role in the development of nociceptive hypersensitivity after carrageenan injection [14] . ()-α-Bisabolol also reduced neuronal excitability in mice sciatic nerves, probably by an irreversible blockade of voltagedependent sodium channels [15a] . Thus, the reduction of nociception exerted by Laserpitium essential oils is most likely related to ()-α-bisabolol and could be explained, at least in part, by the reduced neuronal excitability and by the inhibition of PGs synthesis.
The essential oils also caused a significant dose-dependent antiedematous effect, as measured by a plethysmometer (Figure 2A and .3% for the doses of 25, 50 and 100 mg/kg, respectively (small graph in Fig. 2A ) and ED 50 ± SEM (95% confidence limits) was 36.3 ± 4.5 (6.0-220.7) mg/kg. L. ochridanum essential oil produced maximal effects of 42.1, 45.3 and 68.6% for the doses of 25, 50 and 100 mg/kg, respectively (small graph in Fig. 2B ). The corresponding ED 50 ± SEM (95% confidence limits) was 45.1 ± 11.3 (1.9-1085.6) mg/kg. The reference drug, indomethacin (8 mg/kg; p.o.), produced 70.6% anti-edematous activity. Thus, Laserpitium essential oils were comparable with indomethacin in reducing the inflammatory edema.
In this study, we showed that L. zernyi and L. ochridanum essential oils, besides efficacy in reducing nociception/hyperalgesia, also possess efficacy in reducing edema, as another manifestation of inflammation. Previously, Jakovlev et al.
[15b] demonstrated the dose-dependent anti-edematous effects of ()-α-bisabolol and chamazulene, both in a dose range of 350 -1400 mg/kg (p.o.), in the same model of localized inflammation in the rat [15b]. Orhan et al. [11] observed that α-pinene (500 mg/kg, p.o.) has a moderate ability to reduce paw edema induced by carrageenan injection into the mouse paw. Doses of both Laserpitium essential oils used by us (between 25 and 100 mg/kg, p.o.) were much lower than those used by Jakovlev et al.
[15b] and Orhan et al. [11] . Anti-edematous effects of both examined Laserpitium essential oils are most likely attributed to a minimal effective doses of ()-α-bisabolol and α-pinene, and also chamazulene in L. ochridanum essential oil, or to a possible synergistic interaction between active ingredients in the oils. It is well known that with a synergistic effect between active components the doses of the individual active components can be substantially reduced.
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Figure 2: Time course of the anti-edematous effect of L. zernyi (A) and L. ochridanum (B) essential oils, expressed as volume differences in mL (dv) between edematous and nonedematous right hind paw (after and before carrageenan injection) (larger graph) or as percent of anti-edematous activity (%AE) (smaller graph). Pretreatment (basal) paw volume was obtained before administration of essential oil/indomethacin and induction of inflammation (denoted by arrows)
. Each point represents the mean ± SEM of volume differences (dv) (larger graph) or %AE (smaller graph) obtained in 6-7 animals. Statistical significance (*p < 0.05, **p < 0.01; one-way ANOVA followed by Tukey's HSD test) was determined by comparison with the curve for the vehicle. EO, essential oil; CAR, carrageenan; i.pl., intraplantar.
PGs are also involved in the formation of edema after carrageenan injection [14] . Leukotrienes (LTs) also seem to be important as inhibitors of 5-lipoxygenase (5-LOX), an enzyme involved in their synthesis, reducing carrageenan-induced edema [16a,b] . Experiments in vitro have revealed that ()-α-bisabolol and chamazulene both act as 5-LOX inhibitors [13a] . Thus, the antiedematous effect of the examined oils could be related to the reduction of LT formation, in addition to the previously mentioned reduction of PGs. In conclusion, our results suggest that essential oils from the underground parts of L. zernyi and L. ochridanum could be considered as novel natural products effective against pain and edema present in various inflammatory conditions.
Experimental
Chemicals: Sodium carboxymethyl cellulose (PP1000 Lucel  ) was purchased from Milan Blagojević (Lučani, Serbia). Indomethacin capsules (Serial No: 20145049.) were purchased from Belupo (Koprivnica, Croatia). Ibuprofen was purchased from Pharmagen, GmbH (Germany). Carrageenan was obtained from Sigma-Aldrich Chemie (Germany).
Plant material and isolation of essential oils:
The underground parts (roots and rhizomes) of L. zernyi were collected at Mt. Ošljak, Serbia in July 2008, and those of L. ochridanum from Mt. Galičica, FYROM, in October 2009. Species were identified by Dr M. Niketić, and voucher specimens were deposited at the Natural History Museum in Belgrade under accession number ko20080709 for L. zernyi and ko2008070215 for L. ochridanum. Air-dried, pulverised underground parts of the plants were hydrodistilled in a Clevenger-type apparatus according to the procedure of the European Pharmacopoeia 7.0 [17a], using n-hexane as a collecting solvent.
GC and GC-MS analyses:
The essential oil was analyzed on a SRI 8610C GC-FID system, equipped with DB-5 capillary column (5% phenyl-methylpolysiloxane, 30 m  0.32 mm, film thickness 0.25 μm) and a split/splitless injector (split ratio 1:20; injection volume 1 μL of 3% solution of oil in n-hexane). The column temperature was programmed from 60ºC to 280ºC at a rate of 3ºC/min. The injector and detector temperature was 280ºC. Helium was used as the carrier gas at a flow rate of 1.2 mL/min. GC-MS analysis was carried out using a Hewlett Packard 6890-5973 GC-MS system operating in the EI mode at 70 eV, equipped with a split/splitless injector (split ratio 1:10; 200ºC). The transfer line temperature was 250ºC. Helium was the carrier gas (1 mL/min) and the capillary column used was a HP-5MS (5% phenylmethylpolysiloxane, 30 m × 0.25 mm; film thickness 0.25 μm). The temperature program was the same as that used for the GC analysis. The injected volume was 1 μL 3% solution of oil in n-hexane. Identification of the compounds was based on the comparison of their retention indices (KI), retention times (RT) and mass spectra with those obtained from authentic samples and/or the NIST/NBS, Wiley libraries and the literature [17b,c].
Animals:
Male Wistar rats 180-220 g (Military Academy Breeding Farm, Belgrade, Serbia) were used in this study. All experiments were performed according to a protocol approved by the Institutional Animal Care and Use Committee and were carried out in compliance with the NIH Guide for Care and Use of Laboratory Animals [17d]. The animals, left for at least 3 days for acclimatization to animal room condition, were housed in groups of 4 per cage (42.52719 cm 3 ) and maintained on a 12/12 h light/dark cycle at 22 ± 1°C and 60% relative humidity. Food and water were freely available, except during the experimental procedure. The experiments were performed at the same time, between 8:00 and 16:00 h to avoid diurnal variation in behavioral tests.
Essential oils/drugs administration: Essential oils, ibuprofen and indomethacin were suspended in a vehicle containing 0.5% sodium carboxymethyl cellulose (NaCMC) in distilled water, and sonicated for 15 min for proper distribution. They were administered to fasted rats by oral gavage (p.o.) in a volume of 2 mL/kg. Essential oils/indomethacin were administered 60 min before carrageenan. Ibuprofen was administered at the same time as carrageenan. Carrageenan was suspended in saline (1% w/v), 24 h before the experiment and was injected intraplantarly (i.pl.) into the right hind paw of all animals, in a final volume of 0.1 mL/paw, using a 1 mL syringe and a 26 gauge (0.45  12 mm) needle.
Evaluation of antinociceptive and anti-edematous activity:
Inflammation was induced by an intraplantar (i.pl.) injection of carrageenan into the right hind paw, which was followed by nociceptive hypersensitivity and edema development [14,18a] . The antinociceptive activity of essential oils/ibuprofen was determined by a modified paw-pressure test, which was described in detail previously [18a] . Briefly, the rat was placed with its hind paws on 2 transducer platforms of the apparatus (Hugo Sachs Elektronik, March-Hugstetten, Germany) and force exerted by each paw was measured. The difference between forces (df) applied on healthy (non-inflamed) and inflamed paw was determined after each measurement as: df = force (g) applied on the non-inflamed paw -force (g) applied on the inflamed paw.
Measurements were repeated 4 times at each time point and the average df for each rat was used for further calculations. The pretreatment df-value was obtained before carrageenan or carrageenan + essential oils/ibuprofen administration. The posttreatment df-values were measured at 7 time points during 360 min. In order to express a reduction of the df-value induced by the antinociceptive treatment in test (carrageenan + essential oils/ibuprofen treated) groups in relation to the control (carrageenan treated) group df-value, the percent of antinociceptive activity (%AA) was calculated as: %AA = [(control group average df -df of each rat in the test group) / (control group average df)]  100.
If the df of the rat in the test group was greater than the control group average df, a value of 0%AA was assigned.
The anti-edematous activity was assesed by quantification of the rat paw swelling with a plethysmometer (Ugo Basile, Italy), as described previously [18a] . Basal paw volume was obtained before treatment (carrageenan or carrageenan + essential oils/indomethacin administration). The post-treatment paw volume was measured at 7 time points during 360 min. After each post-treatment paw volume measurement, the difference (dv) between treated (inflamed) and a basal paw volume was calculated as: dv = volume of the inflamed paw (mL) -basal volume of the same paw (mL).
Measurements were repeated 2 times at each time point, and the average dv for each rat was used for further calculations. In order to express a reduction of the dv-value induced by the anti-edematous treatment in the test (carrageenan + essential oils/indomethacin treated) groups in relation to the control (carrageenan treated) group dv-value, the percent of anti-edematous activity (AE%) was calculated according to the following formula: %AE = [(control group average dv -dv of each rat in the test group)] / (control group average dv)]  100.
If the dv of the rat in the test group was greater than the control group average dv, a value of 0%AE was assigned. The values for %AA and %AE were calculated after each measurement of df and dv to establish the time of the peak effect. The ED 50 value (the dose expected to result in 50%AA and 50%AE) with 95% confidence limits was estimated from the corresponding log dose-response curves, constructed from the peak effect values [18b]. For measuring paw pressure and paw volume differences, the experimenter was blinded to the treatment received by the animals.
Statistical analysis: All computations were made according to Tallarida and Murray [18b] . Results are expressed as means  SEM obtained from groups of 5-7 animals. Differences between the corresponding means were verified by an analysis of variance (OneWay ANOVA), followed by Tukey's HSD test (p < 0.05 was considered significant).
